Drugs / CMV-DCs
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03615404 | Oct 2018 → Nov 2019 | brain cancer, glioblastoma, medulloblastoma | Gary Archer Ph.D. | Completed | No outcome recorded |
| Phase 1 | NCT00693095 | Sep 2008 → Dec 2013 | glioblastoma | John Sampson | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-DCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00693095 ↗ |
| Modality | Cell therapy | “Dendritic cells taken from your blood will be "pulsed" or loaded with genetic material called RNA (ribonucleic acid), which stimulates the DC to change the RNA into a protein...” NCT00693095 ↗ |
| Route | Other | “DCs or saline will be given intradermally and divided equally to both inguinal regions.” NCT00693095 ↗ |